Canakinumab groups were categorised as low ( @ mg/kg i.v. once ; N = @ ) , intermediate ( @ and @ mg/kg i.v. once , @ and @ mg s.c. monthly ; N = @ ) , medium ( @ mg/kg i.v. once , @ mg s.c. monthly and @ mg s.c. once ; N = @ ) , and high doses ( @ mg/kg i.v. once and @ mg s.c. monthly ; N = @ ) and compared with placebo ( N = @ ) .